Vaccination News Home Page subscribe Vaccination NewsLetter
http://www.journals.uchicago.edu/JID/journal/issues/v187n8/21059/brief/21059.abstract.html
The Journal of Infectious Diseases 2003;187:1206-1212
© 2003 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2003/18708-0005$15.00
Go to full text | Return to Issue Table of Contents
| MAJOR ARTICLE |
Appropriateness of a Pneumococcal Conjugate Vaccine in Brazil: Potential Impact of Age and Clinical Diagnosis, with Emphasis on Meningitis
Maria-Cristina C. Brandileone,1 Ana-Lucia S. Sgambatti de Andrade,2 José-Luis Di Fabio,3 Maria-Luiza L. S. Guerra,1 and Robert Austrian4
1Secao de
Bacteriologia, Adolfo Lutz Institute,
Secretary of Health for the
State of São Paulo, São
Paulo, and 2Institute of
Tropical Pathology and Public
Health, Federal University of Goiás,
Goiás, Brazil; 3Division of
Vaccines and Immunization, Pan
American Health Organization, Washington,
DC; 4Department of Research
Medicine, University of Pennsylvania,
School of Medicine, Philadelphia
Received 29 August 2002; accepted 10 December 2002; electronically published 26 March 2003.
| The distribution of pneumococcal serotypes in Brazil
was analyzed by age group and clinical diagnosis,
using data obtained during 20 years of national
surveillance. Serotypes 1 and 5 remained among the
main serotypes in all age groups, increasing in
frequency with age. Serotype 14 was prevalent among
children, whereas serotypes 3 and 4 were most
prevalent among the adult population. The potential impact
of the 7- and 9-valent conjugate vaccines on
children up to age 5 years with severe pneumococcal
diseases was 58.2% and 73%, respectively; the highest
coverage of the 7-valent vaccine for pneumonia was
achieved for children aged 7 months to 2 years (70%),
whereas, for meningitis, it was observed for children
aged 7 months to 5 years (58.6%). The use
of conjugate vaccine may be of potential benefit by
reducing the childhood sequelae and mortality of
pneumococcal infection in Brazil.
|
Financial support: Brazilian Council for
Science and Technology Development (grants 520580/00-1 and
520399/00-5); Pan American Health Organization; Canadian
International Development Agency; Instituto Adolfo Lutz; Brazilian
Ministry of Health.
Informed consent was obtained from patients or
guardians, and human experimentation guidelines of the
Brazilian Ministry of Health were followed in the conduct
of the clinical research.
Go to full text | Return to Issue Table of Contents
ALL INFORMATION, DATA, AND
MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION
PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS
OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR
LEGAL ADVICE. THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND
COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH
YOUR HEALTH CARE PROVIDER.